Could the next trial assignment be known before enrollment?

Put the safeguard at the correct point

Draw a simple timeline with entry confirmed, assignment revealed, and support delivered. Allocation concealment concerns access to the forthcoming assignment before and until assignment. Participant or assessor masking concerns knowledge after that point. A visibly different support format may make later masking difficult while the earlier sequence still can be protected.

Cochrane’s Chapter 8 explicitly separates sequence generation, concealment, and blinding. It explains why advance knowledge can permit selective entry into groups. We use that methodological distinction, not a formal risk-of-bias rating or an accusation about a named trial. A label in a title does not show who could see a forthcoming assignment or when.

Cochrane: Cochrane Handbook, Chapter 8: Assessing risk of bias in a randomized trial

Use an invented enrollment comparison

Imagine two fictional studies using a chance-generated sequence. In one, staff can read the next assignment before settling entry. In the other, the assignment is unavailable until entry is confirmed through the stated process. Both have chance-based sequences, yet they provide different information about whether entry could be influenced by upcoming allocation. The example describes a possibility, not observed misconduct.

A reader does not need to guess which staff member would have preferred a group or claim selection occurred. The appropriate question is whether the procedure prevented advance knowledge and what the report says about its conduct. Keep documentary facts separate from speculation about motives. A hypothetical weakness illustrates why concealment deserves its own methods line, not why all randomized trials are suspect.

Read the process rather than a technology name

A computer, envelope, or centralized service name is not a full explanation by itself. Locate the timing of entry, who accessed the assignment, and what happened before release. Do not attempt to bypass access controls or ask participants for private records to investigate. Use the published description and any relevant protocol or supplementary explanation supplied by the researchers.

Also distinguish intended protection from reported implementation. A protocol can describe a safeguard while the completed report describes problems or leaves conduct unclear. Conversely, missing detail in a news summary may be present in the full paper. Record what material you actually checked before writing an unresolved question. Unavailable information is not proof that a sequence was exposed.

End with one specific methods question

A bounded note says the report describes how the next assignment was protected until this stage, or that the timing and access were unclear. Keep random sequence generation and later masking on separate lines. A strong account of one safeguard does not establish that outcome measurement, follow-up, or clinical applicability were sound. Those remain their own evidence questions.

If a treatment choice depends on the research, seek qualified interpretation of the complete report rather than assigning your own quality score from one detail. This guide does not teach trial administration or prove a quitting effect. Its practical output is a before-assignment timeline and an exact clarification request, preventing a broad blinded label from answering a different question than the one you intended to ask.